

TDMS No. 99023 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

beta-Myrcene

CAS Number: 123-35-3

F1_M3

Date Report Reqsted: 07/26/2007

Time Report Reqsted: 09:29:40

First Dose M/F: 04/11/02 / 04/10/02

Lab: BAT

C Number: C99023

Lock Date: 12/22/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

TDMSE Version: 1.8.0

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident				3
Moribund Sacrifice	7	6	8	12
Natural Death	8	9	11	14
Survivors				
Natural Death	1			
Terminal Sacrifice	34	35	31	21
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Inflammation	2 [1.0]	6 [1.2]	3 [1.3]	8 [2.0]
Necrosis				5 [2.2]
Muscularis, Degeneration		3 [1.3]		
Gallbladder	(49)	(49)	(49)	(49)
Intestine Large, Cecum	(49)	(48)	(49)	(47)
Edema			1 [2.0]	
Lymphoid Tissue, Hyperplasia		2 [2.5]		
Intestine Small, Duodenum	(49)	(47)	(47)	(48)
Inflammation, Chronic Active				1 [3.0]
Necrosis				2 [2.0]
Intestine Small, Ileum	(49)	(47)	(47)	(47)
Intestine Small, Jejunum	(49)	(47)	(49)	(45)
Peyer's Patch, Hyperplasia, Lymphoid			2 [3.5]	
Liver	(50)	(50)	(50)	(50)
Abscess				1
Amyloid Deposition	1 [3.0]		1 [3.0]	
Angiectasis		1 [1.0]	2 [2.5]	
Basophilic Focus	3	7	6	2
Clear Cell Focus	15	21	21	2
Degeneration, Cystic			1 [1.0]	
Eosinophilic Focus	16	23	21	18
Fatty Change	25 [1.6]	18 [1.6]	16 [1.6]	29 [1.4]
Hematopoietic Cell Proliferation	3 [1.3]	2 [1.0]	2 [1.5]	1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Infarct		2 [4.0]		
Inflammation, Chronic Active	26 [1.0]	24 [1.1]	23 [1.0]	17 [1.0]
Mineralization			2 [1.5]	7 [1.0]
Mixed Cell Focus	13	3	6	3
Necrosis	7 [2.0]	10 [1.8]	13 [1.9]	17 [1.9]
Pigmentation, Ceroid	1 [2.0]			
Pigmentation, Hemosiderin	2 [2.0]	4 [1.3]		2 [1.0]
Tension Lipidosis	3 [1.0]	5 [1.6]	4 [1.5]	7 [1.3]
Thrombosis	1 [2.0]			
Vacuolization Cytoplasmic	3 [2.0]	3 [2.0]	4 [2.5]	23 [2.6]
Hepatocyte, Hypertrophy	1 [1.0]	2 [1.5]	16 [1.7]	38 [2.6]
Hepatocyte, Pigmentation, Hemosiderin			1 [1.0]	
Oval Cell, Hyperplasia		3 [2.3]	2 [1.5]	
Mesentery	(4)	(7)	(5)	(3)
Necrosis		1 [4.0]		
Fat, Necrosis	4 [2.0]	5 [2.0]	4 [1.8]	2 [2.0]
Pancreas	(50)	(50)	(50)	(50)
Atrophy	1 [1.0]	1 [1.0]		2 [1.5]
Cytoplasmic Alteration	1 [1.0]		1 [1.0]	2 [1.5]
Inflammation				1 [2.0]
Necrosis, Focal				1 [1.0]
Duct, Cyst				1 [4.0]
Salivary Glands	(50)	(50)	(50)	(50)
Inflammation	1 [2.0]		1 [2.0]	1 [2.0]
Stomach, Forestomach	(50)	(50)	(49)	(50)
Inflammation	10 [1.8]	9 [1.8]	13 [1.8]	23 [1.5]
Mineralization	1 [1.0]			
Necrosis	1 [1.0]	1 [2.0]	1 [1.0]	6 [1.3]
Ulcer	4 [2.3]	4 [1.8]	7 [1.4]	9 [2.1]
Epithelium, Hyperplasia	12 [2.1]	17 [1.6]	16 [2.0]	28 [1.9]
Epithelium, Metaplasia			1 [3.0]	
Stomach, Glandular	(50)	(50)	(50)	(50)
Dysplasia	1 [2.0]			
Hyperplasia	2 [2.0]	1 [1.0]	1 [2.0]	2 [1.0]
Inflammation	1 [1.0]		1 [2.0]	2 [1.0]
Metaplasia, Squamous		1 [1.0]	1 [1.0]	1 [1.0]
Necrosis			1 [1.0]	2 [1.5]
Muscularis, Hypertrophy	1 [2.0]			
Tongue	(1)	(0)	(0)	(0)
Tooth	(38)	(33)	(35)	(13)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Dysplasia	38	31	35	13
Gingiva, Inflammation	1 [2.0]			
Periodontal Tissue, Inflammation	1 [2.0]	1 [3.0]		
Pulp, Inflammation	1 [2.0]	3 [1.3]	1 [1.0]	
CARDIOVASCULAR SYSTEM				
Blood Vessel	(0)	(2)	(1)	(2)
Mineralization		1 [1.0]		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	15 [1.1]	12 [1.1]	13 [1.1]	19 [1.0]
Fibrosis		1 [2.0]		
Inflammation	2 [1.5]	1 [2.0]		
Mineralization	2 [2.0]	1 [1.0]	4 [1.5]	7 [1.6]
Necrosis		1 [2.0]		
Atrium, Thrombosis	1 [1.0]		2 [2.5]	1 [1.0]
Coronary Artery, Inflammation	3 [1.0]			
Vein, Venule, Thrombosis		1 [1.0]		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Amyloid Deposition	1 [2.0]			
Hypertrophy	7 [1.3]	4 [1.5]	10 [1.3]	
Necrosis				1 [1.0]
Thrombosis			1 [1.0]	
Subcapsular, Hyperplasia	46 [1.6]	47 [1.7]	46 [1.7]	43 [1.5]
Zona Fasciculata, Atrophy		1 [3.0]		
Zona Fasciculata, Hyperplasia		1 [1.0]	3 [1.3]	2 [1.0]
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 [1.0]	2 [1.0]		
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	38 [1.2]	36 [1.3]	28 [1.3]	18 [1.1]
Infiltration Cellular, Mixed Cell			1 [2.0]	
Pituitary Gland	(49)	(49)	(50)	(49)
Pars Distalis, Hyperplasia	1 [1.0]	1 [3.0]		
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation				1 [1.0]
Mineralization	1 [1.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
C-cell, Hyperplasia	1 [3.0]		1 [1.0]	1 [1.0]
Follicle, Cyst	1 [1.0]	3 [1.0]		1 [2.0]
Follicle, Degeneration	1 [1.0]	1 [4.0]		2 [1.0]
Follicular Cell, Hyperplasia		4 [2.3]		2 [2.0]
Follicular Cell, Hypertrophy	1 [2.0]	1 [1.0]		
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Cyst	1 [1.0]		1 [3.0]	
Fibrosis	1 [1.0]			
Granuloma Sperm	1 [1.0]			
Inflammation			2 [2.0]	
Mineralization				1 [1.0]
Preputial Gland	(50)	(50)	(50)	(50)
Ectasia	4 [2.3]	5 [2.4]	4 [2.0]	3 [2.3]
Inflammation	5 [2.8]	3 [2.7]	2 [3.5]	2 [1.5]
Prostate	(50)	(50)	(50)	(50)
Atrophy			1 [2.0]	
Hyperplasia		2 [2.0]		
Inflammation	25 [1.1]	15 [1.1]	22 [1.0]	12 [1.0]
Seminal Vesicle	(50)	(50)	(50)	(50)
Atrophy			1 [3.0]	
Inflammation			1 [3.0]	
Testes	(50)	(50)	(50)	(50)
Germinal Epithelium, Degeneration	5 [1.2]	2 [2.0]	5 [2.2]	18 [1.3]
Germinal Epithelium, Mineralization			2 [1.0]	2 [1.5]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Atrophy	1 [2.0]		1 [2.0]	18 [2.3]
Myelofibrosis	1 [1.0]		1 [1.0]	1 [1.0]
Necrosis, Focal		1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Pigmentation		1 [2.0]	1 [2.0]	1 [2.0]
Myeloid Cell, Hyperplasia	1 [2.0]	3 [2.0]	3 [1.7]	1 [4.0]
Lymph Node	(2)	(0)	(5)	(1)
Inguinal, Atrophy			1 [3.0]	
Inguinal, Infiltration Cellular, Histiocyte			1 [2.0]	
Mediastinal, Inflammation, Granulomatous			1 [2.0]	
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Atrophy	3 [3.0]	6 [1.2]	9 [1.6]	23 [2.1]
Hyperplasia, Lymphoid		3 [1.7]	2 [3.0]	
Infiltration Cellular, Plasma Cell	1 [3.0]	3 [2.0]	1 [1.0]	
Lymph Node, Mesenteric	(49)	(50)	(47)	(44)
Amyloid Deposition	1 [1.0]			
Atrophy	12 [1.9]	12 [1.7]	13 [2.3]	28 [2.6]
Hyperplasia, Lymphoid		2 [1.5]	1 [2.0]	
Infiltration Cellular, Plasma Cell		1 [2.0]		
Inflammation	1 [2.0]			
Inflammation, Granulomatous			1 [4.0]	
Pigmentation, Hemosiderin	1 [2.0]			
Spleen	(49)	(50)	(48)	(49)
Amyloid Deposition	1 [2.0]		1 [1.0]	
Hematopoietic Cell Proliferation	33 [1.8]	43 [1.9]	41 [2.2]	10 [1.9]
Hyperplasia, Lymphoid	1 [2.0]		1 [3.0]	2 [2.0]
Infiltration Cellular, Histiocyte			1 [2.0]	1 [2.0]
Pigmentation, Hemosiderin	1 [1.0]	1 [1.0]		2 [1.5]
Lymphoid Follicle, Atrophy	7 [2.1]	5 [2.2]	10 [2.9]	31 [3.3]
Lymphoid Follicle, Hyperplasia			1 [2.0]	
Thymus	(47)	(47)	(48)	(47)
Amyloid Deposition	1 [1.0]			
Atrophy	45 [2.4]	40 [2.3]	44 [2.6]	41 [3.0]
Hyperplasia, Lymphoid				1 [2.0]
Infiltration Cellular, Plasma Cell				1 [2.0]
Necrosis				1 [3.0]
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Infiltration Cellular, Mast Cell, Focal		1 [3.0]		
Inflammation	1 [2.0]		2 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Ulcer	1 [3.0]	2 [3.5]	3 [4.0]	
Hair Follicle, Inflammation	1 [2.0]			
Sebaceous Gland, Hyperplasia				1 [3.0]
Subcutaneous Tissue, Edema			1 [2.0]	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibrous Osteodystrophy				1 [4.0]
Osteoporosis		1 [3.0]		
Joint, Arthrosis	1 [4.0]			
Skeletal Muscle	(0)	(2)	(1)	(1)
Inflammation		1 [2.0]		1 [2.0]
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Vein, Infiltration Cellular, Lymphocyte			1 [1.0]	
Peripheral Nerve	(0)	(0)	(1)	(0)
Infiltration Cellular, Lymphocyte			1 [2.0]	
Spinal Cord	(0)	(0)	(1)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Abscess				1
Foreign Body				1
Hematopoietic Cell Proliferation			1 [2.0]	
Inflammation, Suppurative			1 [2.0]	1 [1.0]
Inflammation, Chronic Active	2 [1.5]	1 [1.0]	1 [1.0]	3 [1.3]
Thrombosis			1 [1.0]	1 [1.0]
Alveolar Epithelium, Hyperplasia	4 [1.5]	8 [2.0]	5 [2.4]	5 [1.8]
Alveolus, Infiltration Cellular, Histocyte	4 [2.5]	9 [1.8]	1 [2.0]	3 [2.0]
Arteriole, Degeneration		1 [1.0]		
Bronchiole, Hyperplasia	1 [1.0]	2 [2.0]		1 [2.0]
Glands, Inflammation		2 [1.5]	1 [2.0]	
Nose	(50)	(50)	(50)	(50)
Inflammation	3 [2.3]	2 [2.0]	2 [1.5]	3 [1.7]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Polyp, Inflammatory Glands, Dilatation	6 [2.3]	3 [1.7]	1 [1.0]	
Olfactory Epithelium, Degeneration	5 [1.2]	5 [1.2]	7 [1.1]	6 [1.2]
Olfactory Epithelium, Metaplasia, Respiratory	7 [2.3]	2 [2.0]	1 [2.0]	
Respiratory Epithelium, Hyperplasia	1 [1.0]	1 [2.0]		
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Fibrosis			1 [3.0]	
Thrombosis				1 [3.0]
Cornea, Hyperplasia, Squamous		2 [2.0]		
Cornea, Inflammation		2 [2.0]		1 [1.0]
Lens, Cataract		2 [3.0]		
Optic Nerve, Fibrosis	1 [2.0]	1 [2.0]		
Retina, Degeneration		2 [1.5]		
Harderian Gland	(50)	(50)	(50)	(50)
Fibrosis	1 [2.0]	1 [3.0]		
Hyperplasia	1 [2.0]	3 [2.7]	2 [1.0]	2 [2.5]
Inflammation				1 [4.0]
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet			3 [1.7]	
Infarct	6 [2.2]	6 [1.7]	7 [1.6]	1 [3.0]
Mineralization	31 [1.0]	31 [1.0]	29 [1.0]	12 [1.3]
Nephropathy	44 [1.4]	44 [1.6]	43 [1.3]	27 [1.3]
Cortex, Cyst	6 [1.0]	6 [1.3]	4 [1.0]	3 [1.7]
Cortex, Inflammation	1 [4.0]	2 [3.0]		
Cortex, Metaplasia, Osseous	1 [1.0]			
Papilla, Inflammation	1 [3.0]	2 [2.5]		1 [2.0]
Papilla, Necrosis	1 [4.0]	1 [1.0]	1 [2.0]	
Pelvis, Dilatation			1 [3.0]	
Pelvis, Inflammation	1 [2.0]		2 [2.0]	
Renal Tubule, Hyperplasia	14 [1.3]	16 [1.1]	14 [1.1]	6 [1.2]
Renal Tubule, Necrosis			3 [1.3]	18 [2.3]
Renal Tubule, Pigmentation,	1 [2.0]	2 [4.0]	1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Reqsted: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Hemosiderin				
Renal Tubule, Vacuolization Cytoplasmic	39 [1.2]	41 [1.3]	20 [1.1]	
Urinary Bladder	(50)	(50)	(49)	(49)
Inflammation			1 [3.0]	

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident		1	1	
Moribund Sacrifice	4	5	6	5
Natural Death	7	10	8	28
Survivors				
Terminal Sacrifice	39	34	35	17
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Inflammation	2 [1.0]	1 [2.0]	4 [2.5]	
Necrosis			2 [2.5]	
Muscularis, Degeneration	1 [1.0]		1 [1.0]	
Gallbladder	(47)	(50)	(50)	(49)
Intestine Large, Cecum	(49)	(50)	(50)	(47)
Edema			1 [3.0]	
Inflammation			1 [2.0]	
Epithelium, Metaplasia			1 [2.0]	
Intestine Large, Colon	(50)	(50)	(50)	(47)
Parasite Metazoan				1 [1.0]
Epithelium, Inflammation			1 [1.0]	
Intestine Large, Rectum	(50)	(49)	(50)	(49)
Inflammation			1 [1.0]	
Necrosis			1 [2.0]	
Intestine Small, Jejunum	(50)	(48)	(49)	(40)
Peyer's Patch, Hyperplasia, Lymphoid			3 [2.3]	
Serosa, Fibrosis		1 [2.0]		
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 [2.0]	1 [3.0]	2 [2.0]	
Basophilic Focus	2	1	4	1
Clear Cell Focus		1	1	
Cytoplasmic Alteration				1 [1.0]
Eosinophilic Focus	4	5	6	9
Fatty Change	29 [1.6]	35 [1.4]	16 [1.3]	15 [1.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Hematopoietic Cell Proliferation	6 [1.2]	1 [2.0]	1 [2.0]	1 [1.0]
Infiltration Cellular, Lymphocyte		4 [2.3]	1 [1.0]	
Inflammation, Suppurative				1 [2.0]
Inflammation, Chronic Active	43 [1.0]	35 [1.1]	34 [1.0]	14 [1.1]
Mineralization				1 [1.0]
Mixed Cell Focus	1	4	6	1
Necrosis	3 [1.3]	2 [1.5]	3 [1.7]	7 [1.7]
Pigmentation, Hemosiderin	2 [1.0]		2 [1.0]	
Regeneration		1 [3.0]		
Tension Lipidosis	12 [1.0]	3 [1.0]	10 [1.3]	4 [1.8]
Vacuolization Cytoplasmic	6 [2.5]	11 [1.7]	8 [3.6]	30 [2.8]
Bile Duct, Crystals			1 [2.0]	
Bile Duct, Hyperplasia		1 [2.0]	1 [2.0]	
Hepatocyte, Hypertrophy			6 [1.5]	40 [2.0]
Oval Cell, Hyperplasia	1 [4.0]		1 [3.0]	
Mesentery	(15)	(18)	(3)	(0)
Fat, Necrosis	14 [1.9]	15 [2.6]	1 [1.0]	
Pancreas	(50)	(49)	(50)	(48)
Atrophy	2 [4.0]	1 [3.0]	3 [3.3]	1 [4.0]
Basophilic Focus			1 [1.0]	
Inflammation, Granulomatous			1 [2.0]	
Mineralization				1 [2.0]
Necrosis				1 [2.0]
Acinus, Cytoplasmic Alteration, Focal		1 [1.0]		
Duct, Cytoplasmic Alteration			1 [2.0]	
Salivary Glands	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte		1 [2.0]		
Stomach, Forestomach	(50)	(49)	(50)	(47)
Inflammation	2 [1.5]	5 [1.4]	8 [1.4]	19 [1.5]
Mineralization				1 [1.0]
Necrosis			4 [1.3]	6 [1.5]
Ulcer	3 [1.7]	2 [2.0]	3 [2.0]	8 [1.8]
Epithelium, Hyperplasia	7 [2.0]	10 [1.5]	17 [1.8]	24 [1.5]
Stomach, Glandular	(50)	(50)	(50)	(49)
Cytoplasmic Alteration, Focal	1 [1.0]			
Inflammation	1 [1.0]			2 [1.0]
Mineralization				1 [2.0]
Necrosis				2 [1.0]
Tooth	(1)	(3)	(4)	(0)
Dysplasia	1	3	4	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
CARDIOVASCULAR SYSTEM				
Blood Vessel	(2)	(2)	(2)	(1)
Inflammation, Chronic Active	1 [2.0]			
Mineralization	1 [3.0]	2 [3.0]		
Aorta, Inflammation				1 [2.0]
Carotid Artery, Intima, Hyperplasia			1 [4.0]	
Media, Degeneration	1 [2.0]			
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	7 [1.0]	1 [1.0]	4 [1.0]	4 [1.0]
Degeneration		1 [2.0]		
Fibrosis			1 [2.0]	1 [3.0]
Inflammation	1 [3.0]	2 [4.0]		
Mineralization	1 [1.0]	2 [1.5]	2 [1.0]	5 [1.2]
Pigmentation, Hemosiderin		1 [1.0]		
Atrium, Thrombosis			1 [1.0]	
Coronary Artery, Inflammation	1 [2.0]		1 [2.0]	
Epicardium, Inflammation		1 [3.0]		
Valve, Thrombosis	2 [3.0]	2 [4.0]		1 [4.0]
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hypertrophy			3 [1.0]	
Capsule, Fibrosis		1 [2.0]		
Capsule, Infiltration Cellular, Lymphocyte		1 [2.0]		
Subcapsular, Hyperplasia	50 [2.8]	50 [2.7]	49 [2.9]	50 [2.4]
Zona Fasciculata, Hyperplasia	1 [2.0]	2 [1.0]		
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 [2.0]	2 [3.0]		
Parathyroid Gland	(47)	(34)	(43)	(44)
Cyst		1 [2.0]		
Hyperplasia	1 [2.0]			
Infiltration Cellular, Lymphocyte	1 [1.0]			
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Hyperplasia	1 [2.0]	2 [2.5]	5 [1.6]	2 [2.0]
Pars Intermedia, Hyperplasia			1 [2.0]	
Pars Nervosa, Inflammation		1 [1.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Thyroid Gland	(50)	(50)	(50)	(50)
Inflammation	2 [1.0]	2 [1.0]		1 [1.0]
C-cell, Hyperplasia			1 [1.0]	
Follicle, Cyst	1 [1.0]	1 [2.0]	3 [1.7]	3 [1.7]
Follicle, Degeneration	1 [1.0]			
Follicular Cell, Hyperplasia	2 [1.5]	1 [1.0]	3 [1.0]	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(49)	(48)	(50)	(49)
Ovary	(50)	(50)	(49)	(49)
Amyloid Deposition			1 [2.0]	
Angiectasis	1 [3.0]	2 [2.5]	1 [2.0]	2 [1.5]
Atrophy	43 [2.6]	44 [3.2]	45 [3.3]	43 [3.0]
Hyperplasia, Tubular			1 [2.0]	2 [1.5]
Inflammation			1 [1.0]	
Inflammation, Granulomatous		1 [1.0]		
Thrombosis	1 [4.0]			1 [4.0]
Corpus Luteum, Cyst		2 [1.0]	1 [1.0]	
Follicle, Cyst	5 [2.2]	4 [1.5]	4 [2.0]	
Follicle, Cyst, Multiple			1 [3.0]	
Germinal Epithelium, Cyst	1 [2.0]	2 [1.5]	1 [3.0]	1 [4.0]
Germinal Epithelium, Cyst, Multiple			1 [2.0]	
Periovarian Tissue, Cyst		1 [2.0]	1 [1.0]	
Rete Ovarii, Cyst		1 [4.0]		2 [3.5]
Oviduct	(0)	(0)	(1)	(0)
Uterus	(50)	(50)	(50)	(50)
Angiectasis		1 [2.0]	1 [2.0]	2 [1.5]
Thrombosis			1 [2.0]	
Endometrium, Hyperplasia	43 [2.9]	33 [2.3]	28 [2.3]	23 [1.7]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(49)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Atrophy	1 [2.0]		7 [2.6]	29 [2.6]
Myelofibrosis	16 [1.4]	9 [1.3]	4 [1.5]	3 [1.3]
Necrosis		1 [2.0]		
Myeloid Cell, Hyperplasia	2 [1.5]	1 [3.0]	1 [2.0]	
Lymph Node	(7)	(8)	(7)	(0)
Bronchial, Hyperplasia, Lymphoid	1 [3.0]		1 [2.0]	
Inguinal, Infiltration Cellular, Plasma Cell	1 [1.0]			
Renal, Amyloid Deposition	1 [2.0]			
Renal, Ectasia	1 [4.0]			
Renal, Infiltration Cellular, Plasma Cell	1 [1.0]			
Lymph Node, Mandibular	(50)	(50)	(49)	(49)
Amyloid Deposition	1 [1.0]			
Atrophy	4 [1.5]	8 [1.3]	11 [1.5]	22 [1.5]
Hyperplasia, Lymphoid	3 [3.0]	2 [2.5]	1 [2.0]	1 [4.0]
Infiltration Cellular, Plasma Cell	1 [1.0]			
Lymph Node, Mesenteric	(47)	(48)	(44)	(39)
Atrophy	9 [1.8]	7 [2.0]	5 [2.0]	25 [2.5]
Hyperplasia, Lymphoid	1 [1.0]			
Spleen	(49)	(50)	(50)	(50)
Amyloid Deposition	1 [1.0]			
Hematopoietic Cell Proliferation	39 [1.7]	39 [1.8]	16 [2.3]	11 [1.6]
Hyperplasia, Lymphoid	6 [2.3]	4 [2.5]	4 [2.5]	1 [2.0]
Infiltration Cellular, Plasma Cell	1 [1.0]	1 [2.0]		
Pigmentation, Hemosiderin	9 [1.1]	16 [1.3]	11 [1.3]	14 [1.3]
Lymphoid Follicle, Atrophy	4 [2.0]	11 [2.6]	11 [2.9]	32 [3.6]
Lymphoid Follicle, Hyperplasia			1 [2.0]	
Thymus	(49)	(48)	(47)	(48)
Amyloid Deposition	1 [2.0]			
Atrophy	22 [2.0]	14 [3.1]	19 [2.9]	38 [3.3]
Hyperplasia, Atypical			1 [2.0]	
Infiltration Cellular, Plasma Cell	1 [2.0]	1 [3.0]		
Inflammation		1 [2.0]		
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia			1 [2.0]	
Duct, Dilatation			1 [2.0]	
Skin	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Ulcer			1 [4.0]	
Hair Follicle, Inflammation, Diffuse		1 [2.0]		
Sebaceous Gland, Hyperplasia, Focal			1 [3.0]	
Subcutaneous Tissue, Fibrosis	1 [2.0]	1 [3.0]		
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Joint, Degeneration	1 [2.0]			
Tibia, Osteosclerosis	1 [2.0]			
Skeletal Muscle	(0)	(3)	(0)	(0)
Inflammation		1 [2.0]		
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Cerebellum, Necrosis			1 [2.0]	
Cerebrum, Necrosis			1 [3.0]	
Hippocampus, Necrosis			1 [3.0]	
Medulla, Demyelination, Focal		1 [2.0]		
Vein, Infiltration Cellular, Lymphocyte	1 [2.0]		1 [2.0]	
Peripheral Nerve	(0)	(1)	(0)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid				1 [2.0]
Inflammation, Suppurative		1 [3.0]		
Inflammation, Chronic Active	4 [1.3]	1 [1.0]	1 [2.0]	3 [1.0]
Pigmentation, Hemosiderin			1 [1.0]	
Alveolar Epithelium, Hyperplasia	2 [2.5]	3 [1.7]	2 [2.5]	5 [2.2]
Alveolus, Infiltration Cellular, Histocyte	5 [1.4]		3 [2.0]	1 [1.0]
Bronchiole, Hyperplasia	1 [2.0]	1 [2.0]		1 [2.0]
Serosa, Fibrosis, Focal	1 [3.0]			
Serosa, Inflammation, Suppurative				1 [2.0]
Nose	(50)	(50)	(50)	(50)
Olfactory Epithelium, Degeneration	2 [1.5]	5 [1.0]	5 [1.0]	12 [1.1]
Olfactory Epithelium, Metaplasia,		1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Respiratory Respiratory Epithelium, Hyperplasia Trachea Epithelium, Glands, Cytoplasmic Alteration	1 [2.0] (50)	(50)	(50) 1 [2.0]	(50)
SPECIAL SENSES SYSTEM				
Ear Necrosis	(0)	(0)	(1) 1 [3.0]	(0)
Eye Atrophy Synechia	(50) 1 [4.0]	(50)	(50) 1 [2.0]	(49)
Cornea, Inflammation	1 [3.0]	1 [2.0]	1 [1.0]	
Lens, Cataract			2 [1.0]	
Retina, Retinal Detachment			1 [2.0]	
Harderian Gland Fibrosis	(50) 1 [3.0]	(50)	(50)	(49)
Hyperplasia	1 [1.0]	2 [3.0]	1 [1.0]	
URINARY SYSTEM				
Kidney Accumulation, Hyaline Droplet	(50)	(50)	(50)	(50) 1 [3.0]
Amyloid Deposition		1 [4.0]	1 [4.0]	
Infarct	4 [1.8]	4 [1.0]	3 [2.7]	1 [1.0]
Infiltration Cellular, Lymphocyte	1 [3.0]	3 [2.0]	4 [2.0]	
Mineralization	10 [1.5]	13 [1.0]	8 [1.4]	8 [1.3]
Nephropathy	20 [1.1]	21 [1.1]	16 [1.4]	16 [1.0]
Cortex, Cyst	1 [3.0]			
Cortex, Metaplasia, Osseous		2 [1.5]		
Glomerulus, Amyloid Deposition	1 [3.0]			
Papilla, Inflammation	1 [2.0]	2 [2.0]		2 [1.5]
Papilla, Necrosis	2 [2.0]		1 [2.0]	
Pelvis, Dilatation			1 [3.0]	
Renal Tubule, Hyperplasia		1 [1.0]	1 [1.0]	
Renal Tubule, Necrosis	2 [3.0]	2 [1.0]	2 [2.5]	17 [2.4]
Ureter	(0)	(0)	(1)	(0)
Urinary Bladder	(50)	(50)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

beta-Myrcene

Time Report Reqsted: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Infiltration Cellular, Lymphocyte Arteriole, Inflammation	1 [2.0]	2 [2.5] 1 [2.0]		1 [3.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)